Antihypertensives and Prostanoids



Acute hypertension managed with intravenous antihypertensives has an all-cause in-hospital mortality rate of nearly 7%; with 59% of patients developing worsening organ dysfunction.1 The cost of hypertension associated with a secondary diagnosis in hospitalized patients is $2,734.2 Currently, national treatment guidelines for acute hypertension are not available for adult intensive care unit (ICU) patients. Recently, a survey was conducted to evaluate the management of acute hypertension.3 This survey discovered that only 8.2% of responders had a guideline in place to treat acute hypertension in non-stroke patients. There is also substantial variability in the intravenous agents selected to treat acute hypertension.1,3 In regards to the number of patients admitted to the ICU with acute hypertension, physicians surveyed reported that approximately five patients are admitted with a hypertensive emergency to their ICU each month and approximately the same number develop a hypertensive emergency during their ICU stay.3 With the frequency of acute hypertension and the safety concerns associated with intravenous antihypertensive agents, a review of the medications commonly used in the ICU to treat acute hypertension in special populations was conducted.


Peritoneal Dialysis Safety Concern Liver Dysfunction Continuous Renal Replacement Therapy Hypertensive Emergency 


  1. 1.
    Katz JN, Gore JM, Amin A, et al. on behalf of the STAT Investigators. Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: results from the Studying the Treatment of Acute hyper Tension Registry. Am Heart J. 2009;158:599-606.Google Scholar
  2. 2.
    Wang G, Zhang Z, Ayala C. Hospitalization costs associated with hypertension as a secondary diagnosis among insured patients aged 18–64 years. Am J Hypertens. 2010;23:275-281.PubMedGoogle Scholar
  3. 3.
    Benson J, Gerlach A, Dasta J. National survey of acute hypertension management. Crit Care Shock. 2008;11:154-166.Google Scholar
  4. 4.
    Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425-1436.PubMedGoogle Scholar
  5. 5.
    McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477-1482.PubMedGoogle Scholar
  6. 6.
    Barst RJ, Rubin LJ, Long WA, McGoon MD, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334(5):296-302.PubMedGoogle Scholar
  7. 7.
    Gokhman R, Smithburger PL, Seybert AL, Kane-Gill SL. Pharmacokinetic Rationale for Combination Therapy in Pulmonary Arterial Hypertension. J Cardiovasc Pharmacol 2010;56(6):686-695.Google Scholar
  8. 8.
    Gessler T, Seeger W, Schmehl T. Inhaled prostainaoids in the therapy of pulmonary hypertension. J Aerosol Med Pulm Drug Deliv. 2008;21(1):1-12.PubMedGoogle Scholar
  9. 9.
    Flaherty JF, Wong B, LaFollette G, Warnock DG, Julse JD, Gambertoglio JG. Pharmacokinetics of esmolol and ASL-8123 in renal failure. Clin Pharmacol Ther. 1989;45:321-327.PubMedGoogle Scholar
  10. 10.
    Turlapaty P, Laddu A, Murthy VS, Singh B, Lee R. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings. Am Heart J. 1987;114:866-885.PubMedGoogle Scholar
  11. 11.
    Lowenthal DT, Porter S, Saris SD, et al. Clinical pharmacology, pharmacodynamics and interactions with esmolol. Am J Cardiol. 1985;56:14F-18F.PubMedGoogle Scholar
  12. 12.
    Buchi KN, Rollins DE, Tolman KG, et al. Pharmacokinetics of esmolol in hepatic disease. J Clin Pharmacol. 1987;27:880-884.PubMedGoogle Scholar
  13. 13.
    Esmolol hydrochloride injection (package insert). Bedford, OH: Bedford Laboratories, Inc.; August 2008.Google Scholar
  14. 14.
    Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2005;112(12):e154-e235.PubMedGoogle Scholar
  15. 15.
    Felix SB, Stangl V, Kieback A, et al. Acute hemodynamic effects of beta-blockers in patients with severe congestive heart failure: comparison of celiprolol and esmolol. J Cardiovasc Pharmacol. 2001;38:666-671.Google Scholar
  16. 16.
    Barbier GH, Shettigar UR, Appunn DO. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol. Int J Clin Pharmacol Ther. 1995;33:212-218.PubMedGoogle Scholar
  17. 17.
    Anonymous. Intravenous esmolol for the treatment of supraventricular tachyarrhytmia: results of a multicenter, baseline-controlled safety and efficacy study in 160 patients. Am Heart J. 1986;112:498-505.Google Scholar
  18. 18.
    Askenazi J, MacCosbe PE, Hoff J, Turlapaty P, Hua TA, Laddu A. Hemodynamic effects of esmolol, an ultra-short acting beta blocker. J Clin Pharmacol. 1987;27:567-573.PubMedGoogle Scholar
  19. 19.
    Angaran DM, Schultz NJ, Tschida VH. Esmolol hydrochloride: an ultrashort-acting, β-adrenergic blocking agent. Clin Pharm. 1986;5:288-303.PubMedGoogle Scholar
  20. 20.
    Lowenthal DT, Porter RS, Schari R, Turapaty P, Laddu AR, Matier WL. Esmolol-digoxin drug interaction. J Clin Pharmacol. 1987;27:561-566.PubMedGoogle Scholar
  21. 21.
    Shettigar UR, Toole JG, Appunn DO. Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation and flutter. Am Heart J. 1993;126:368-374.PubMedGoogle Scholar
  22. 22.
    Sagie A, Strasberg B, Kusnieck J, Sclarovsky S. Symptomatic bradycardia induced by the combination of oral diltiazem and beta blockers. Clin Cardiol. 1991;14:314-316.PubMedGoogle Scholar
  23. 23.
    Leor J, Levartowsky D, Sharon C, Farfel Z. Amiodarone and B-adrenergic blockers: An interaction with metoprolol but not with atenolol. Am Heart J. 1988;116:206-207.PubMedGoogle Scholar
  24. 24.
    Cheymol G, Poirier JM, Carrupt PA, Testa B, et al. Pharmacokinetics of β-adrenoceptor blockers in obese and normal volunteers. Br J Clin Pharmacol. 1997;43:563-570.PubMedGoogle Scholar
  25. 25.
    Walstad RA, Berg Kj, Wessel-Aas T, Nilsen OG. Labetalol in the treatment of hypertension in patients with normal and impaired renal function. Acta Med Scand Suppl. 1982;665:135-141.PubMedGoogle Scholar
  26. 26.
    Wood AJ, Ferry DG, Bailey RR. Elimination kinetics of labetalol in severe renal failure. Br J Clin Pharmacol. 1982;13(suppl 1):81S-86S.PubMedGoogle Scholar
  27. 27.
    Thompson FD, Joekes AM, Hussein MM. Monotherapy with labetalol for hypertensive patients with normal and impaired renal function. Br J Clin Pharmacol. 1979;8(suppl 2):129S-133s.PubMedGoogle Scholar
  28. 28.
    MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983;3:193-219.PubMedGoogle Scholar
  29. 29.
    Labetalol hydrochloride injection (package insert). Bedford, OH: Bedford Laboratories, Inc.; June 2000.Google Scholar
  30. 30.
    Halstenson Ce, Opsahl JA, Pence TV, et al. The disposition and dynamics of labetalol in patients on dialysis. Clin Pharmacol Ther. 1986;40:462-468.PubMedGoogle Scholar
  31. 31.
    Homeida M, Jackson L, Roberts CJ. Decreased first-pass metabolism of labetalol in chronic liver disease. Br Med J. 1978;2:1048-1050.PubMedGoogle Scholar
  32. 32.
    Wilson DJ, Wallin JD, Vlachakis ND, et al. Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies. Am J Med. 1983;75:95-102.PubMedGoogle Scholar
  33. 33.
    Rosei EA, Trust PM, Brown JJ. Intravenous labetalol in severe hypertension. Lancet. 1975;2:1093-1094.PubMedGoogle Scholar
  34. 34.
    Marik PE, Varon J. Hypertensive crises challenges and management. Chest. 2007;131:1949-1962.PubMedGoogle Scholar
  35. 35.
    Bailey RR. Labetalol in the treatment of patients with hypertension and renal function impairment. Br J Clin Pharmacol. 1979;8(suppl 2):135S-140S.PubMedGoogle Scholar
  36. 36.
    Williams JG, DeVoos K, Craswell PW. Labetalol in the treatment of hypertensive renal patients. Med J Aust. 1978;25:225-228.Google Scholar
  37. 37.
    Clark JA, Zimmerman HJ, Tanner LA. Labetalol hepatotoxicity. Ann Intern Med. 1990;113:210-213.PubMedGoogle Scholar
  38. 38.
    Douglas DD, Yang Rd, Jensen P, Thiele DL. Fatal labetalol-induced injury. Am J Med. 1989;87:235-236.PubMedGoogle Scholar
  39. 39.
    Mason JM, Dickinson HO, Nicolson DJ, Campbell F, et al. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens. 2005;23:1777-1781.PubMedGoogle Scholar
  40. 40.
    Kunz I, Schorr U, Klaus S, Sharma AM. Resting metabolic rate and substrate use in obesity hypertension. Hypertension. 2000;36:26-32.PubMedGoogle Scholar
  41. 41.
    Lopressor (metoprolol tartrate). Suffern, NY: Novartis Pharmaceuticals Corporation; 2009.Google Scholar
  42. 42.
    Lloyd P, John VA, Signy M, Smith SE. The effect of impaired renal function on the pharmacokinetics of metoprolol after single administration of a 14/190 metoprolol OROS system. Am Heart J. 1990;20(2):478-482.Google Scholar
  43. 43.
    Seiler KU, Schuster KJ, Meyer GJ, et al. The pharmacokinetics of metoprolol and its metabolites in dialysis patients. Clin Pharmacokinet. 1980;5(2):192-198.PubMedGoogle Scholar
  44. 44.
    Bennett WM, Aronoff GR, Morrison G, et al. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis. 1983;3:155-193.PubMedGoogle Scholar
  45. 45.
    Bortolotti A, Castelli D, Verotta D, Bonati M. Pharmacokinetic and pharmacodynamic modeling of metoprolol in rabbits with liver failure. Eur J Drug Metab Pharmacokinet. 1989;14(2):145-151.PubMedGoogle Scholar
  46. 46.
    Ross PJ, Lewis MJ, Sheridan DJ, et al. Adrenergic hypersensitivity after beta-blocker withdrawal. Br Heart J. 1981;45:637-642.PubMedGoogle Scholar
  47. 47.
    Fishman WH. Bea-adrenergic blocker withdrawal. Am J Cardiol. 1987;59(13):26f-32f.Google Scholar
  48. 48.
    Walden RJ, Tomlinson B, Bhattacharjee P, Prichard BN. The beta-adrenergic blockade phenomenon. J Pharmacol. 1983;14(2):35-48.PubMedGoogle Scholar
  49. 49.
    Cleviprex (package insert). Parsippany, NJ: The Medicines Company; 2008.Google Scholar
  50. 50.
    Phung OJ, Baker WL, White CM, Coleman CI. Focus on clevidipine. Formulary. 2009;44(4):102-107.Google Scholar
  51. 51.
    Deeks ED, Keating GM, Keam SJ. Clevidipine: a review of its use in the management of acute hypertension. Am J Cardiovasc Drugs. 2009;9(2):117-134.PubMedGoogle Scholar
  52. 52.
    Vuylsteke A, Milner Q, Ericsson H, et al. Pharmacokinetics and pulmonary extraction of clevidipine, a new vasodilating ultrashort-acting dihydropyridine, during cardiopulmonary bypass. Br J Anaesth. 2000;85(5):683-689.PubMedGoogle Scholar
  53. 53.
    Ericsson H, Tholander B, Regardh CG. In vitro hydrolysis rate and protein-binding of clevidipine, a new ultrashort-acting calcium antagonist metabolized by esterases, in different animal species and man. Eur J Pharm Sci. 1999;8(1):29-37.PubMedGoogle Scholar
  54. 54.
    Pollack CV, Varon J, Garrison NA, et al. Clevidipine, and intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. Ann Emerg Med. 2009;53:329-338.PubMedGoogle Scholar
  55. 55.
    Aronson S, Dyke CM, Stierer KA, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg. 2008;107:1110-1121.PubMedGoogle Scholar
  56. 56.
    Ericsson H, Bredburg U, Eriksson U, et al. Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers. Anesthesiology. 2000;92:993-1001.PubMedGoogle Scholar
  57. 57.
    Levy JH, Mancoa MY, Gitter R, et al. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients” The results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. Anesth Analg. 2007;105:918-925.PubMedGoogle Scholar
  58. 58.
    Erickson AL, DeGrado JR, Fanikos JR. Clevidipine: a short acting intravenous dihydropyridine calcium channel blocker for the management of hypertension. Pharmacotherapy. 2010;30(5):515-528.PubMedGoogle Scholar
  59. 59.
    Dasta J, Boucher B, Brophy G, et al. Intravenous to oral conversion of antihypertensives: a toolkit for guideline development. Ann Pharmacother. 2010;44:1430-1447.PubMedGoogle Scholar
  60. 60.
    Zhang JG, Dehal SS, Ho T, et al. Human Cytochrome P450 induction and inhibition potential of clevidipine and its primary metabolite H152/81. Drug Metab Dispos. 2006;34(5):734-737.PubMedGoogle Scholar
  61. 61.
    Enalaprilat (package insert). Bedford, OH: Bedford Laboratories; June 2005.Google Scholar
  62. 62.
    Elung-Jensen T, Heisterberg J, Kamoer AL, et al. High serum enalaprilat in chronic renal failure. J Renin Angiotensin Aldosterone Syst. 2001;2(4):240-245.PubMedGoogle Scholar
  63. 63.
    Greenbaum R, Zucchelli P, Caspi A, et al. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Br J Clin Pharmacol. 2001;49:23-31.Google Scholar
  64. 64.
    Kelly JG, Doyle GD, Carmody M, et al. Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of hemodialysis. BrJ Clin Pharmacol. 1988;26:781-786.Google Scholar
  65. 65.
    Mirenda J, Edwards C. Prolonged hypotension by enalaprilat in a case of renal artery stenosis. Anesth Analg. 1992;75:1017-1020.PubMedGoogle Scholar
  66. 66.
    Flack JM, Mensah GA, Ferrario CM. Using angiotensin converting enzyme inhibitors in African-American hypertensives: a new approach to treating hypertension and preventing target-organ damage. Curr Med Res Opin. 2000;16:66-79.PubMedGoogle Scholar
  67. 67.
    Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin- converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351-1357.PubMedGoogle Scholar
  68. 68.
    Brown NJ, Ray WA, Snowden M, et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60:8-13.PubMedGoogle Scholar
  69. 69.
    Elliott WJ. Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects. Clin Pharmacol Ther. 1996;60:582-588.PubMedGoogle Scholar
  70. 70.
    Schattner A, Kozak N, Friedman J. Captopril-induced jaundice: report of 2 cases and a review of 13 additional reports in the literature. Am J Med Sci. 2001;322(4):236-240.PubMedGoogle Scholar
  71. 71.
    Chou JW, Yu CJ, Chuang PH, et al. Successful treatment of fosinopril-induced severe cholestatic jaundice with plasma exchange. Ann Pharmacother. 2008;42(12):1887-1892.PubMedGoogle Scholar
  72. 72.
    Hydralazine hydrochloride injection (package insert). Shirley, NY: American Regent; January 2009.Google Scholar
  73. 73.
    Bennett WM, Aronoff GR, Golper TA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians; 1994.Google Scholar
  74. 74.
    Jackson G, Pierscianowski TA, Mahon W, et al. Inappropriate antihypertensive therapy in the elderly. Lancet. 1976;2:1317-1318.PubMedGoogle Scholar
  75. 75.
    Finks SW, Finks AL, Self TH. Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure. South Med J. 2006;99(1):18-22.PubMedGoogle Scholar
  76. 76.
    Vidrio H, Tena I. Hydralazine tachycardia and sympathetic cardiovascular reactivity in normal subjects. Clin Pharmacol Ther. 1980;28:587-591.PubMedGoogle Scholar
  77. 77.
    Gould L, Reddy CVR, Zen B, et al. Electrophysiologic properties of hydralazine in man. Pace Clin Electrophysiol. 1980;3:548-554.Google Scholar
  78. 78.
    Haitas B, Meyer TE, Angel ME, Reef E. Comparative haemodynamic effects of intravenous nisoldipine and hydralazine in congestive heart failure. Br J Clin Pharmacol. 1990;29(3):366-368.PubMedGoogle Scholar
  79. 79.
    Pezzarossa A, Cimicchi MC, Orlandi N, et al. Lack of effect of nicardipine and diltiazem on glucose- and arginine-induced insulin release in obese subjects. Cardiovasc Drugs Ther. 1988;2(5):669-672.PubMedGoogle Scholar
  80. 80.
    Raccah D, Pettenuzzo-Mollo M, Provendier O, et al. Comparison of the effects of captopril and nicardipine on insulin sensitivity and thrombotic profile in patients with hypertension and android obesity CaptISM Study Group. Captopril Insulin Sensitivity Multicenter Study Group. Am J Hypertens. 1994;7(8):731-738.PubMedGoogle Scholar
  81. 81.
    Cardene premixed intravenous injection (nicardipine hydrochloride premixed intravenous injection) package insert. Bedminster, NJ: EKR Therapeutics, Inc.; 2009.Google Scholar
  82. 82.
    Razak TA, McNeil JJ, Sewell BB, et al. The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine. Clin Pharmacol Ther. 1990;47(4):463-469.PubMedGoogle Scholar
  83. 83.
    Reddy P, Yeh YC. Use of injectable nicardipine for neurovascular indications. Pharmacotherapy. 2009;29(4):398-409.PubMedGoogle Scholar
  84. 84.
    Aya AGM, Mangin R, Hoffet M, et al. Intravenous nicardipine for severe hypertension in pre-eclampsia – effects of an acute treatment on mother and fetus. Intensive Care Med. 1999;25:1277-1281.PubMedGoogle Scholar
  85. 85.
    Wang EQ, Fung HL. Effects of obesity on the pharmacodynamics of nitroglycerin in conscious rates. AAPS PharmSci. 2002;4(4):E28.PubMedGoogle Scholar
  86. 86.
    Alpert JS. Nitrate therapy in the elderly. Am J Cardiol. 1990;65:23J-27J.PubMedGoogle Scholar
  87. 87.
    Cahalan MK, Hashimoto Y, Aizawa K, et al. Elderly, conscious patients have an accentuated hypotensive response to nitroglycerin. Anesthesiology. 1992;77:646-655.PubMedGoogle Scholar
  88. 88.
    Nitroglycerin injection (package insert). Shirley, NY: American Regent, Inc.; 2005.Google Scholar
  89. 89.
    Devlin J, Dasta JF, Kleinschmidt K, Varon J. Patterns of antihypertensive use in patients with acute severe hypertension from a non-neurological cause: The STAT Registry. Pharmacotherapy. 2010;30:1087-1096.PubMedGoogle Scholar
  90. 90.
    Wainwright RJ, Foran JPM, Padaria SF, et al. The long-term safety and tolerability of trans­dermal glyceryl trinitrate, when used with a patch-free interval in patients with stable angina. Br J Clin Pharmacol. 1993;47:178-182.Google Scholar
  91. 91.
    Bank J. Migraine with aura after administration of sublingual nitroglycerin tablets. Headache. 2001;41:84-87.PubMedGoogle Scholar
  92. 92.
    Olsson G, Allgen J. Is there an optimal prophylactic nitrate therapy? Eur Heart J. 1991;12(suppl A):21-23.PubMedGoogle Scholar
  93. 93.
    GISSI-3 investigators. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343(8906):1115-1122.Google Scholar
  94. 94.
    Webb DJ, Freestone S, Allen MJ, et al. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol. 1999;83:21C-28C.PubMedGoogle Scholar
  95. 95.
    Rindone JP, Sloane EP. Cyanide toxicity from sodium nitroprusside: risks and management. Ann Pharmacother. 1992;26:515-519.PubMedGoogle Scholar
  96. 96.
    American Heart Association. Guidelines 2005 Cardiopulmonary resuscitation and emergency cardiovascular care. Part 7.4 Monitoring Medications. Circulation 2005;112;Iv-78-IV-83.Google Scholar
  97. 97.
    Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for adults and Children. 5th ed. Philadelphia: American College of Physicians; 2007.Google Scholar
  98. 98.
    Nitropress (sodium nitroprusside) Injection Solution (package insert). Lake Forest, IL: Hospira, Inc.; October 2006.Google Scholar
  99. 99.
    Nessim SL, Richardson RM. Dialysis for thiocyanate intoxication: a case report and review of the literature. ASAIO J. 2006;52:749-781.Google Scholar
  100. 100.
    Lindquist P, Rosling H, Tydent H. Cyanide release from sodium nitroprusside drug in bypass in hypothermia. Acta Anaesthesiol Scand. 1989;33:686-688.Google Scholar
  101. 101.
    Moore RA, Geller EA, Gallagher JD, Clark DL. Effect of hypothermic cardiopulmonary bypass on nitroprusside metabolism. Clin Pharmacol Ther. 1995;37:680-683.Google Scholar
  102. 102.
    Varon J. Treatment of acute severe hypertension. Drugs. 2008;68:283-297.PubMedGoogle Scholar
  103. 103.
    Mann T, Cohn PF, Holman LB, et al. Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Results in 25 patients and comparison with nitroglycerin. Circulation. 1978;57:732-738.PubMedGoogle Scholar
  104. 104.
    Pasch T, Schulz V, Hoppenshauser G. Nitroprusside-induced formation of cyanide and its detoxification with thiosulphate during deliberate hypotension. J Cardiovasc Pharmacol. 1983;5:77-85.PubMedGoogle Scholar
  105. 105.
    Cohn JN, Franciosa JA, Francis GS, et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med. 1982;306:1129-1135.PubMedGoogle Scholar
  106. 106.
    Rhoney D, Peacock WF. Intravenous therapies for hypertensive emergencies, part 1. Am J Health Syst Pharm. 2009;66:1343-1352.PubMedGoogle Scholar
  107. 107.
    Ivankovich AD, Braverman B, Stephens TS, Shulman M, Heyman HJ. Sodium thiosulfate disposition in humans: relation to sodium nitroprusside toxicity. Anesthesiology. 1983;58:11-17.PubMedGoogle Scholar
  108. 108.
    Cheung AT, Cruz-Shiavone GE, Meng QC, et al. Cardiopulmonary bypass, hemolysis and nitroprusside induced cyanide toxicity. Anesth Analg. 2007;105:29-33.PubMedGoogle Scholar
  109. 109.
    Flolan® (package insert). Research Triangle Park, NC: GlaxoSmithKline; January 2008.Google Scholar
  110. 110.
    Moncada S, Vane JR. Prostacyclin and blood coagulation. Drugs. 1981;21:430-437.PubMedGoogle Scholar
  111. 111.
    Zussman RM, Rubin RH, Cato AE, et al. Hemodialysis using prostacyclin instead of heparin as the sole antithrombin agent. N Engl J Med. 1981;304:934-939.Google Scholar
  112. 112.
    Addonizio VP, Fisher CA, Bowen JC, et al. Prostacyclin in lieu of anticoagulation with heparin for extracorporeal circulation. Trans Am Soc Artif Intern Organs. 1981;27:304-307.PubMedGoogle Scholar
  113. 113.
    Hory B, Saint-Miller Y, Perol JC. Prostacyclin as the sole antithrombic agent for acute renal failure hemodialysis. Nephron. 1983;73:669-678.Google Scholar
  114. 114.
    Fiaccadori E, Maggiore U, Rotelli C, et al. Continuous haemofiltration in acute renal failure with prostacyclin as the sole anti-haemostatic agent. Intensive Care Med. 2002;82:586-593.Google Scholar
  115. 115.
    Sulica R, Emre S, Poon M. Medical management of porto-pulmonary hypertension and right heart failure prior to living-related liver transplantation. Congest Heart Fail. 2004;10(4):192-194.PubMedGoogle Scholar
  116. 116.
    Swanson KL, Wiesner RH, Nyberg SL, et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant. 2008;8(11):2445-2453.PubMedGoogle Scholar
  117. 117.
    Jones K. Prostacyclin. In: Peacock AJ, ed. Pulmonary Circulation. A Handbook for Clinicians. London: Chapman & Hall; 1996:115-122.Google Scholar
  118. 118.
    Centers for Disease Control. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension–seven sites, United States, 2003–2006. MMWR Morb Mortal Wkly Rep. 2007;56(8):170-172.Google Scholar
  119. 119.
    Yap RL, Mermel LA. Micrococcus infection in patients receiving epoprostenol by continuous infusion. Eur J Clin Microbiol Infect Dis. 2003;22:704-705.PubMedGoogle Scholar
  120. 120.
    Ventavis® (Iloprost inhalation solution) package insert. South San Francisco, CA: Actelion Pharmaceuticals US; April 2010.Google Scholar
  121. 121.
    Remodulin® (Treprostinil injection) package insert. Research Triangle Park, NC: United Therapeutics Corporation; January 2010.Google Scholar
  122. 122.
    Sakai T, Planinsic EM, Mathier MA, et al. Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end-stage liver disease. Eur Soc Organ Transplant. 2009;22:554-561.Google Scholar
  123. 123.
    Wade MF, Baker FJ, Roscigno R, et al. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. J Clin Pharmacol. 2004;44:83.PubMedGoogle Scholar
  124. 124.
    Laliberte K, Arneson C, Jeffs R, et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remoduln) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004;44(2):209-214.PubMedGoogle Scholar
  125. 125.
    Skoro-Sajer N, Lang IM, Harja E, et al. A clinical comparison of slow-and rapid escalation treprostinil (Remodulin) dosing regimens in patients with pulmonary hypertension. Clin Pharmacokinet. 2008;47(9):611-618.Google Scholar
  126. 126.
    McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an Epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003;41:293-299.PubMedGoogle Scholar
  127. 127.
    Oudiz RJ, Farber HW. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an evidence-based review. Am Heart J. 2009;157:625-635.PubMedGoogle Scholar
  128. 128.
    Tyvaso® (Treprostinil inhalation solution) package insert. Research Triangle Park, NC: United Therapeutics Corporation; July 2009.Google Scholar
  129. 129.
    Tyvaso® inhalation system: care and replacement of the system. Accessed June 14, 2010.

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  1. 1.Department of Pharmacy and TherapeuticsUniversity of PittsburghPittsburghUSA

Personalised recommendations